as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹3,292.9
Change
+62.4 (1.93%)
Open
₹3,230.5
Prev. Close
₹3,230.5
Day High
₹3,298.0
Day Low
₹3,222.6
Volume Analysis
Traded
119,533
Delivered
64,975
Delivery %
54.36%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (27.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (21.1%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,395.14 | ₹3,346.57 | ₹3,319.74 | ₹3,271.17 | ₹3,244.34 | ₹3,195.77 | ₹3,168.94 |
| Fibonacci | ₹3,346.57 | ₹3,317.77 | ₹3,299.97 | ₹3,271.17 | ₹3,242.37 | ₹3,224.57 | ₹3,195.77 |
| Camarilla | ₹3,313.64 | ₹3,306.72 | ₹3,299.81 | ₹3,271.17 | ₹3,285.99 | ₹3,279.08 | ₹3,272.17 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+91.99%
1 Week
-0.48%
1 Month
+12.19%
3 Months
+16.8%
6 Months
+41.08%
1 Year
+81.2%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹652.04
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.47%
Net margin 17.48% × asset turnover 0.58x × equity multiplier 1.23x
Company Overview
Sector
Healthcare
Market Cap
₹53,710 Cr
P/E (TTM)
42.9
ROE
10.7%
Book Value
₹648.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Gland Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Valuation (24/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%); promoter holding is falling. Strong 3-year revenue growth (21.1%).
TopFund Score — Fundamentals Quality
72/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 39.1%
- −Stock is trading at 5.02 times its book value
- −Promoter holding has decreased over last quarter: -6.02%
- −Company has a low return on equity of 9.29% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Allotment of 3739 Equity Shares on exercise of ESOPs
Gland Pharma approved 85,317 ESOP options for 2 employees on November 16, 2026.
Gland Pharma issued €20 million corporate guarantee for Phixen SAS facility; valid till March 31, 2030.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 | 1,834 |
| Expenses + | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 | 1,350 |
| Operating Profit | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 | 484 |
| OPM % | 24.0% | 23.0% | 23.0% | 19.0% | 21.0% | 26.0% | 24.0% | 24.0% | 21.0% | 26.0% | 29.0% | 27.0% | 26.0% |
| Other Income + | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 | 69 |
| Interest | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 | 7 |
| Depreciation | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 | 115 |
| Profit before tax | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 | 431 |
| Tax % | 33.0% | 32.0% | 35.0% | 34.0% | 36.0% | 32.0% | 35.0% | 31.0% | 35.0% | 28.0% | 28.0% | 27.0% | 33.0% |
| Net Profit + | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 | 291 |
| EPS in Rs | 12 | 12 | 12 | 9 | 10 | 12 | 11 | 13 | 11 | 16 | 22 | 19 | 18 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 32 | 65 | 96 | 16 | 2 | -10 | -7 | 7 | 6 | 22 | 22 | 20 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 994 | 1,348 | 1,479 | 1,620 | 2,044 | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 7,072 |
| Expenses + | 678 | 845 | 854 | 1,085 | 1,338 | 1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,801 | 5,151 |
| Operating Profit | 316 | 502 | 625 | 535 | 706 | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,921 |
| OPM % | 32.0% | 37.0% | 42.0% | 33.0% | 35.0% | 36.0% | 38.0% | 34.0% | 28.0% | 24.0% | 23.0% | 25.0% | 27.0% |
| Other Income + | 30 | 37 | 34 | 49 | 66 | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 281 |
| Interest | 17 | 16 | 6 | 4 | 4 | 7 | 3 | 5 | 7 | 26 | 42 | 33 | 25 |
| Depreciation | 57 | 63 | 74 | 78 | 82 | 95 | 99 | 110 | 147 | 345 | 378 | 424 | 443 |
| Profit before tax | 272 | 459 | 578 | 502 | 686 | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 | 1,734 |
| Tax % | 23.0% | 32.0% | 28.0% | 36.0% | 34.0% | 22.0% | 25.0% | 25.0% | 26.0% | 32.0% | 34.0% | 30.0% | — |
| Net Profit + | 209 | 314 | 414 | 321 | 452 | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,236 |
| EPS in Rs | 14 | 20 | 27 | 21 | 29 | 50 | 61 | 74 | 47 | 47 | 42 | 62 | 75 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 43.0% | 42.0% | 32.0% | — |
| Sales growth | 0 | 36 | 10 | 10 | 26 | — | 32 | 27 | -18 | 56 | -1 | 14 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,379 | 1,662 | 2,074 | 2,395 | 2,847 | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,341 | 10,669 |
| Borrowings + | 166 | 117 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 372 | 314 | 284 | 251 |
| Other Liabilities + | 197 | 292 | 378 | 512 | 655 | 435 | 588 | 671 | 814 | 1,515 | 1,708 | 1,807 | 1,990 |
| Total Liabilities | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 | 12,927 |
| Fixed Assets + | 649 | 788 | 872 | 843 | 929 | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 | 4,397 |
| CWIP | 192 | 202 | 161 | 199 | 123 | 188 | 338 | 191 | 177 | 238 | 151 | 342 | 450 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 155 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 917 | 1,096 | 1,441 | 1,887 | 2,471 | 2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | 7,614 | 8,080 |
| Total Assets | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 | 12,927 |
| Equity Capital | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | 220 | 476 | 202 | 185 | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from Investing Activity + | — | -12 | -100 | -359 | -319 | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 188 |
| Cash from Financing Activity + | — | -93 | -116 | -4 | -3 | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Net Cash Flow | — | 115 | 260 | -160 | -136 | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 803 |
| Free Cash Flow | — | 33 | 360 | 117 | 50 | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | 67 | 102 | 67 | 58 | 99 | 70 | 79 | 66 | 98 | 100 | 91 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 13.93% | 13.32% | 8.46% | 8.33% | 8.33% | 8.0% | 7.93% | 7.63% | 7.62% | 7.52% | 9.06% | 10.68% |
| Promoters | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.01% |
| FII | 4.05% | 3.59% | 6.88% | 4.48% | 5.04% | 6.9% | 7.39% | 7.9% | 7.58% | 7.29% | 8.74% | 10.36% |
| DII | 24.17% | 25.23% | 32.83% | 35.37% | 34.8% | 33.27% | 32.86% | 32.63% | 32.99% | 33.36% | 30.44% | 33.21% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gland Pharma Limited (this stock) | 53,710 | 42.9 | 5.01 | 10.7% |
| Anthem Biosciences Ltd | 51,355 | 81.4 | 15.65 | 22.3% |
| Biocon Limited. | 58,962 | 86.5 | 1.69 | 1.4% |
| Ipca Laboratories Ltd | 46,508 | 32.3 | 5.36 | 15.7% |
| Fortis Healthcare Ltd | 61,047 | 56.9 | 5.81 | 11.2% |
| Glaxosmithkline Pharma Lt | 45,576 | 40.2 | 24.22 | 45.6% |
| Alkem Laboratories Ltd. | 61,875 | 28.6 | 4.16 | 18.9% |
Which Mutual Funds Hold Gland Pharma Limited?
Frequently Asked Questions about Gland Pharma Limited
Gland Pharma Limited (GLAND) closed at ₹3,292.9 on NSE on 19 November 2026, up 62.4 (1.93%) from the previous close.
Gland Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol GLAND.
Gland Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 42.9.
Gland Pharma Limited has a dividend yield of 0.62%.
Gland Pharma Limited's 52-week high is ₹3,429.0 and its 52-week low is ₹1,574.0.
Gland Pharma Limited has a market capitalisation of ₹53,710 crore.
Gland Pharma Limited has a TopFund Quality Score of 72/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gland Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.